DBV Technologies (DBVT) – Research Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for DBV Technologies (NASDAQ: DBVT):

• 10/30/2026 – DBV Technologies had its “buy” rating reaffirmed by HC Wainwright.
• 10/30/2026 – DBV Technologies had its price target lowered by Guggenheim from $51.00 to $46.00. They now have a “buy” rating on the stock.
• 10/29/2026 – DBV Technologies had its “market outperform” rating reaffirmed by Citigroup.
• 10/29/2026 – DBV Technologies had its price target lowered by Citizens Jmp from $55.00 to $47.00. They now have a “market outperform” rating on the stock.
• 10/15/2026 – DBV Technologies had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 9/30/2026 – DBV Technologies had its “market outperform” rating reaffirmed by Citigroup.

DBV Technologies Trading Up 3.0%

DBVT traded up $0.34 during trading on Wednesday, hitting $11.85. 162,208 shares of the company’s stock traded hands, compared to its average volume of 319,339. The company’s 50 day simple moving average is $10.97 and its two-hundred day simple moving average is $16.59. DBV Technologies S.A. has a 12-month low of $8.63 and a 12-month high of $26.18. The stock has a market capitalization of $745.10 million, a price-to-earnings ratio of -3.94 and a beta of -0.84.

DBV Technologies (NASDAQ:DBVT) last posted its quarterly earnings results on Wednesday, October 28th. The company reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.41). DBV Technologies had a negative return on equity of 120.95% and a negative net margin of 5,392.17%. The business had revenue of $1.60 million during the quarter, compared to analysts’ expectations of $0.56 million. On average, equities analysts expect that DBV Technologies S.A. will post -2.22 EPS for the current year.

DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. Founded in France, the company’s research centers on epicutaneous immunotherapy, an approach that delivers small amounts of an allergen through the skin using a patch. Its lead investigational program is Viaskin Peanut, a patch-based treatment being developed for peanut allergy. DBV has also conducted research into treatments for other conditions, including milk allergy and eosinophilic esophagitis.